RxDoctor Payments Data

Michael Devitt, MD

Internal Medicine · Charlottesville, VANPI 1174812010

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,236 of the $3,651 with a category attached, or 88.6%. 4 manufacturers reported payments, led by Sanofi at 47.5% of the total. Reporting peaked in 2020 at $1,736 and has fallen 96.0% since, to $70 in 2025.

$3,651in general payments, 2019–2025

Across 8 payments — averaging $456.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$2K
  • Seagen Inc.$2K
  • Exelixis Inc.$244
  • Pfizer$147
$3,537,564in research payments, 2019–2025

Across 251 payments — averaging $14,094 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Seagen Inc.$3.1M
  • Pfizer$261K
  • Merck$132K
  • Veru Inc.$75K

What the payments were for

  • Consulting fees$3,23689%
  • Food & beverage$41511%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi1$1,736
Seagen Inc.2$1,525
Exelixis Inc.2$244
Pfizer3$147

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,651 in reported general payments places this provider in the 85th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$69,286
Medicare patients
199
Services billed
938

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide12$165,659
ErleadaApalutamide12$156,953
Abiraterone Acetate143$136,806
OrgovyxRelugolix34$85,420
EliquisApixaban13$17,063
Prednisone89$636
Oxycodone Hcl16$85
Ondansetron Hcl11$64

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$147$17,06313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →